drugset / Trial / NCT02908334

Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis

NCT02908334

RandomizedCrossoverOpen-labelTreatment

Summary

In this study patients will be randomized 1:2 to receive either standard of care treatment or standard of care + Sertraline 200mg/day for 2 weeks, then 400 mg/day for 50 weeks for treatment of disseminated and meningeal coccidioidomycosis.

Timeline

Start
2016-11
Primary completion
2019-01-22
Completion
2019-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Sertraline Small molecule 400 mg

Indications